Auour Investments LLC Acquires New Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Auour Investments LLC bought a new position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 177,000 shares of the company’s stock, valued at approximately $662,000. Auour Investments LLC owned about 0.21% of Atea Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Federated Hermes Inc. acquired a new stake in shares of Atea Pharmaceuticals in the 1st quarter valued at approximately $14,812,000. Tyrus Capital S.A.M. acquired a new stake in shares of Atea Pharmaceuticals in the 4th quarter valued at approximately $6,061,000. Vanguard Group Inc. boosted its stake in shares of Atea Pharmaceuticals by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 6,729,203 shares of the company’s stock valued at $48,584,000 after purchasing an additional 947,321 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Atea Pharmaceuticals by 14.6% in the 1st quarter. BlackRock Inc. now owns 6,624,693 shares of the company’s stock valued at $47,830,000 after purchasing an additional 843,496 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new position in shares of Atea Pharmaceuticals in the 1st quarter valued at $2,293,000. Institutional investors and hedge funds own 72.10% of the company’s stock.

Atea Pharmaceuticals Stock Performance

Shares of Atea Pharmaceuticals stock traded down $0.01 on Friday, hitting $3.27. The stock had a trading volume of 144,905 shares, compared to its average volume of 541,847. Atea Pharmaceuticals, Inc. has a twelve month low of $2.94 and a twelve month high of $6.77. The firm has a market capitalization of $272.72 million, a P/E ratio of -2.56 and a beta of 0.18. The stock has a 50 day moving average of $3.44 and a 200 day moving average of $3.58.

Atea Pharmaceuticals (NASDAQ:AVIR) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.13. Equities analysts expect that Atea Pharmaceuticals, Inc. will post -1.8 earnings per share for the current year.

Analyst Ratings Changes

Separately, JPMorgan Chase & Co. cut Atea Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Thursday, August 10th.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19.